home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

New Lead For Tailored Cancer Therapy

  June, 28 2001 23:14
your information resource in human molecular genetics
Mutant mice lacking cyclin D1 are entirely resistant to breast tumours induced by neu and ras, genes implicated in most human breast cancers, but are susceptible to those tumours caused by the other oncogenes c-myc and Wnt-1. So Piotr Sicinsky and colleagues of the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, report in this week’s Nature (Vol. 411, No. 6841, 28 Jun 2001).

Although it remains to be seen whether these findings translate to humans, the results suggest that those human breast cancers caused by neu and ras could be treated with anti-cyclin D1 therapy. Cyclin D1 is one of many proteins involved in cell proliferation.

"It might one day be possible to provide tailor-made treatments," say Jiri Bartek and Jiri Lukas of the Institute of Cancer Biology, Danish Cancer Society, Copenhagen, in an accompanying News and Views article. Molecular profiles of breast-cancer patients could be drawn up using DNA chips, or assays.


Piotr Sicinsky
tel +1 617 632 5005
e-mail Peter_Sicinski@dfci.harvard.edu

Jiri Bartek
tel +45 35 25 73 57
e-mail bartek@biobase.dk

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.